Absci Corp

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Absci Corp reports solid Q1 performance, highlights platform efficiency

Absci Corp's Q1 2024 performance reflects a focus on innovation with significant R&D investment and revenue generation, supported by a strong cash position
The company's hybrid business model and progress on internal pipeline programs showcase efficiency and commitment to advancing multiple therapeutic candidates

Absci Corp reports strong Q2 earnings, expands oncology programs

Absci Corp's Q2 2024 earnings call highlighted strong financials, progress in pipeline programs, and strategic collaborations with MSK and other partners.
The company's focus on immunology and oncology, supported by AI capabilities and a healthy cash position, positions Absci for future growth and innovation.
While facing challenges in managing R&D expenses and advancing validation studies, Absci has opportunities to drive innovation and establish a leading position in the market.
Overall, Absci's performance in Q2 2024 reflects a company poised for growth, with a solid foundation to drive research, development, and strategic partnerships.

Absci Corp reports solid Q3 earnings, eyes strategic partnerships for growth

Absci Corp's Q3 2024 performance reflects steady revenue growth, prudent cost management, and strong cash reserves.
The company's strategic collaborations and upcoming R&D Day signal a focus on innovation, partnerships, and future growth.
While challenges in managing expenses persist, Absci Corp's opportunities lie in expanding partnerships, showcasing technology, and driving market interest.
Overall, Absci Corp's emphasis on execution, upcoming catalysts, and financial discipline positions it for continued success in the biotech sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

VANCOUVER, Wash., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced it will report financial results for the third quarter 2021 on Tuesday, November 9, 2021. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

Absci to Report Third Quarter Financial Results on November 9, 2021

Celldex Therapeutics

Graphite Bio

Toast

ZoomInfo Technologies

FMR LLC, the Boston-based asset management company commonly known as Fidelity, disclosed this month that its top-five trades during September included new buys in Toast Inc. ( TOST , Financial), Graphite Bio Inc. ( GRPH , Financial) and Absci Corp. ( ABSI , Financial), as well as major position boosts in ZoomInfo Technologies Inc. ( ZI , Financial) and Celldex Therapeutics Inc. ( CLDX , Financial).

FMR LLC's Top 5 Buys in September

EQRx and Absci Corporation (NASDAQ: ABSI) have announced a discovery collaboration for protein-based therapeutics. Deal terms were not disclosed.

EQRx, Absci Ink Protein-Based Therapeutics Development Pact

CAMBRIDGE, Mass., & VANCOUVER, Wash.--(BUSINESS WIRE)--EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced a discovery collaboration. The partnership will leverage Absci's Drug Creation™ technology for discovery and

EQRx and Absci Announce Partnership to Discover and Develop Next-Generation Protein-Based Drugs

New York, New York--(Newsfile Corp. - September 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Absci Corporation ("Absci" or the "Company") (NASDAQ: ABSI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Absci and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Absci Corporation - ABSI

VANCOUVER, Wash., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating virtually in the upcoming BofA Securities 2021 Tech Solutions for Drug Discovery Conference.

Absci to Participate in the BofA Securities 2021 Tech Solutions for Drug Discovery Conference

VANCOUVER, Wash., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter ended June 30, 2021.

Absci Reports Second Quarter 2021 Financial and Operating Results

VANCOUVER, Wash., July 26, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (“Absci”), the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, today announced the closing of its initial public offering of 14,375,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 1,875,000 shares of common stock, at a public offering price of $16.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Absci were $230.0 million. Absci's common stock began trading on the Nasdaq Global Select Market on July 22, 2021, under the ticker symbol “ABSI.” All shares in the offering were offered by Absci.

Absci Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Absci Corp., a Vancouver company behind a multi-faceted drug development platform, went public on Thursday. It's another sign of snowballing interest in new approaches to drug development – a traditionally risky business.

Shares of protein discovery platform Absci pop in market debut

Couchbase

Ryan Specialty Group Holdings

Zenvia

Zevia PBC

Couchbase, Ryan Specialty Group, and four other companies are scheduled to list their shares Thursday as the surge of IPOs continues.

Couchbase and 5 Other Companies Are Going Public. What You Need to Know.

Absci Corp. received a warm reception on Wall Street Thursday, as the shares of the Washington-based provider of an artificial intelligence-powered drug creation platform opened 31.2% above the initial public offering price. The company said overnight that the IPO priced at $16 a share, which was in the middle of the expected range of between $15 and $17 a share.

Absci's stock soars in public debut, as first trade values company at more than $TK billion

Absci, a synthetic biology company whose platform technology aids in the drug discovery process, is going public today.

IPO Day With Absci CEO Sean McClain - The Google Of Synthetic Biology (Video)

VANCOUVER, Wash., July 21, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (“Absci”), the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, today announced the pricing of its initial public offering of 12,500,000 shares of common stock at a public offering price of $16.00 per share. All of the shares of common stock are being offered by Absci. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Absci, are expected to be $200.0 million, excluding any exercise of the underwriters' option to purchase additional shares. Absci's common stock is expected to begin trading on the Nasdaq Global Select Market on July 22, 2021, under the ticker symbol “ABSI.” The offering is expected to close on July 26, 2021, subject to the satisfaction of customary closing conditions. In addition, Absci has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

Absci Announces Pricing of Initial Public Offering

AbSci Proposes Terms For $200 Million IPO

AbSci Corp. has set terms of its initial public offering, which could value the Washington-based provider of an artificial intelligence-powered drug creation platform could be valued at up to $1.54 billion. The company is looking to raise up to $212.5 million, as it is offering 12.5 million shares in the IPO, which is expected to price between $15 and $17 a share.

AbSci sets IPO terms, valuing company at up to $1.5 billion

News for Absci Corp Stock (ABSI)